

2018 Trigeminal Neuralgia Drug Development- Pipeline Analysis Report

<https://marketpublishers.com/r/284146D2CCEEN.html>

Date: April 2018

Pages: 0

Price: US\$ 999.00 (Single User License)

ID: 284146D2CCEEN

Abstracts

Trigeminal neuralgia is one of the most painful clinical conditions causing sudden, intense, recurrent pain usually on one side of face supplied with trigeminal nerve. It affects around 65 to 275 thousand population in the US. The intense pain is evoked by activities affecting the nerve such as talking, eating, smoking etc. Mouth, face and scalp are affected areas.

Trigeminal Neuralgia pipeline comprises of 9 active drugs under active development as of April 2018. Of these, 4 drugs are in phase 2. Further, 4 drugs are in Pre-clinical stage and 1 drug in research stage.

17 companies are developing the pipeline for Trigeminal Neuralgia. Of this, Biogen Inc and Capnia, Inc. have received orphan drug status for their therapeutic candidates.

To assist researchers and business development managers, VPA Research has come up with a comprehensive report on Trigeminal Neuralgia pipeline. The report provides insights into different therapeutic candidates in preclinical, research, discovery, NDA/IND, pre registration, phase 1, phase 2, and phase 3 trials). Drugs under development directly and through combination with other drugs are also included.

Current status, developmental phase, participating companies and entities, recent developments, orphan drug/fast track/other designations, drug class are provided for each Trigeminal Neuralgia pipeline product. Mechanism of Action and the target area of the pipeline product are also provided. Further, clinical and preclinical trials along with results of the trials are also included in the report.

In addition to complete details of each product, the report provides key trends in

Trigeminal Neuralgia pipeline studies. The products under development are categorized according to their development phase, mechanism and company to provide detailed insights into the type of drugs being developed and the stages of development.

Contents

1 TABLE OF CONTENTS

1.1 LIST OF FIGURES

1.2 LIST OF TABLES

2 EXECUTIVE SUMMARY

2.1 DISEASE OVERVIEW

2.2 PIPELINE SNAPSHOT

2.3 PIPELINE DRUGS BY PHASE

2.4 PIPELINE DRUGS BY COMPANY

2.5 PIPELINE DRUGS BY MECHANISM OF ACTION

3 TRIGEMINAL NEURALGIA- COMPANY WISE PIPELINE ANALYSIS

3.1 Allodynic Therapeutics, LLC PIPELINE, H1 2018

3.2 Biogen Inc PIPELINE, H1 2018

3.3 Capnia, Inc. PIPELINE, H1 2018

3.4 Grace Therapeutics LLC PIPELINE, H1 2018

3.5 InMed Pharmaceuticals Inc PIPELINE, H1 2018

3.6 KPI Therapeutics, Inc. PIPELINE, H1 2018

3.7 Merz Pharma GmbH & Co. KGaA PIPELINE, H1 2018

3.8 OliPass Corporation PIPELINE, H1 2018

3.9 PixarBio Corporation PIPELINE, H1 2018

4 TRIGEMINAL NEURALGIA DRUG SNAPSHOTS

4.1 BIIB074 DRUG DETAILS

4.1.1 Snapshot

4.1.2 Drug Overview

4.1.3 Mechanism of Action

4.1.4 Current Status

4.1.5 Trial Details

4.2 Nasal CO2 DRUG DETAILS

4.2.1 Snapshot

4.2.2 Drug Overview

4.2.3 Mechanism of Action

- 4.2.4 Current Status
- 4.2.5 Trial Details
- 4.3 GTX-201 DRUG DETAILS
 - 4.3.1 Snapshot
 - 4.3.2 Drug Overview
 - 4.3.3 Mechanism of Action
 - 4.3.4 Current Status
- 4.4 INM-405 DRUG DETAILS
 - 4.4.1 Snapshot
 - 4.4.2 Drug Overview
 - 4.4.3 Mechanism of Action
 - 4.4.4 Current Status
- 4.5 CSP-4 DRUG DETAILS
 - 4.5.1 Snapshot
 - 4.5.2 Drug Overview
 - 4.5.3 Mechanism of Action
 - 4.5.4 Current Status
- 4.6 incobotulinumtoxinA DRUG DETAILS
 - 4.6.1 Snapshot
 - 4.6.2 Drug Overview
 - 4.6.3 Mechanism of Action
 - 4.6.4 Current Status
 - 4.6.5 Trial Details
- 4.7 OLP-1002 DRUG DETAILS
 - 4.7.1 Snapshot
 - 4.7.2 Drug Overview
 - 4.7.3 Mechanism of Action
 - 4.7.4 Current Status
- 4.8 NeuroRelease NR14 DRUG DETAILS
 - 4.8.1 Snapshot
 - 4.8.2 Drug Overview
 - 4.8.3 Mechanism of Action
 - 4.8.4 Current Status
- 4.9 ALLOD-2 DRUG DETAILS
 - 4.9.1 Snapshot
 - 4.9.2 Drug Overview
 - 4.9.3 Mechanism of Action
 - 4.9.4 Current Status

5 RECENT DEVELOPMENTS IN TRIGEMINAL NEURALGIA PIPELINE

5.1 Capnia Granted Orphan Designation for Nasal CO₂ for the Treatment of Trigeminal Neuralgia- 2015

5.2 InMed Pharmaceuticals, Inc. Updates Pain Program- 2017

5.3 Merz and Teijin Announce Partnership to Bring Xeomin® (incobotulinumtoxinA) to Japan - 2017

5.4 PixarBio Corporation Clarifies Pathways to FDA Approval for NR14 to Treat “Trigeminal Neuralgia” and Post-Surgical Pain - 2018

6 APPENDIX

6.1 ABOUT VPA RESEARCH

6.2 SOURCES AND RESEARCH METHODOLOGY

List Of Figures

LIST OF FIGURES

Figure 1: Trigeminal Neuralgia Pipeline by Phase, H1- 2018

Figure 2: Trigeminal Neuralgia Pipeline by Companies, H1- 2018

Figure 3: Company wise Pipeline Drug Phases, H1- 2018

Figure 4: Trigeminal Neuralgia Pipeline by Mechanism of Action, H1- 2018

Figure 5: Mechanism wise Pipeline Drug Phases, H1- 2018

List Of Tables

LIST OF TABLES

- Table 1: Trigeminal Neuralgia Pipeline by Phase, H1- 2018
- Table 2: Trigeminal Neuralgia Pipeline by Companies, H1- 2018 (1)
- Table 3: Trigeminal Neuralgia Pipeline by Mechanism of Action, H1- 2018
- Table 4: Allodynic Therapeutics, LLC Trigeminal Neuralgia Pipeline, H1- 2018
- Table 5: Biogen Inc - Trigeminal Neuralgia Pipeline, H1- 2018
- Table 6: Capnia, Inc. Trigeminal Neuralgia Pipeline, H1- 2018
- Table 7: Grace Therapeutics LLC - Trigeminal Neuralgia Pipeline, H1- 2018
- Table 8: InMed Pharmaceuticals Inc Trigeminal Neuralgia Pipeline, H1- 2018
- Table 9: KPI Therapeutics, Inc. - Trigeminal Neuralgia Pipeline, H1- 2018
- Table 10: Merz Pharma GmbH & Co. KGaA Trigeminal Neuralgia Pipeline, H1- 2018
- Table 11: OliPass Corporation - Trigeminal Neuralgia Pipeline, H1- 2018
- Table 12: PixarBio Corporation Trigeminal Neuralgia Pipeline, H1- 2018

I would like to order

Product name: 2018 Trigeminal Neuralgia Drug Development- Pipeline Analysis Report

Product link: <https://marketpublishers.com/r/284146D2CCEEN.html>

Price: US\$ 999.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/284146D2CCEEN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970